2
Translational Relevance
Lung cancer is the leading cause of cancer mortality and therapies directly targeting HER2 aberrations in lung cancer remain an unmet clinical need. Here we generated three mouse models that recapitulated the clinical setting: HER2 wt as an oncogene driver, co-overexpression of HER2 with EGFR mutation and the activating HER2 mutation. Treatment studies using the third-generation tyrosine kinase inhibitor osimertinib demonstrated that not all HER2 aberrations should be treated equally. While osimertinib showed robust efficacy as a monotherapy for HER2 wt , its combination with BET inhibitor JQ1 was most efficacious for HER2 mutation. Therefore, our results not only provide a strong rationale for clinical evaluation of osimertinib against HER2-driven lung cancers, but also highlights the need to tailor treatment strategies for different HER2 aberrations.
Research.
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Introduction
Lung cancer is the leading cause of cancer related mortality and non-small cell lung cancer (NSCLC) makes up about 85% of all lung cancers (1) . There are three subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma and large cell carcinoma (1) .
The rapid progress of targeted therapies appears mainly in lung adenocarcinomas with specific oncogenic drivers, especially EGFR and ALK mutations (2) (3) (4) . For EGFR mutations, three generations of tyrosine kinase inhibitors (TKIs) have been developed and are currently being used in lung cancer treatment (5) .
HER2 is another receptor tyrosine kinase in ErbB/HER family and forms heterodimers with other family members such as EGFR to activate downstream signaling (6, 7) . Compared with the recent clinical progress for EGFR TKIs, HER2
targeting remains an urgent clinical need in NSCLC. HER2 amplification and overexpression drive oncogenesis in several cancer types, such as breast, ovarian and gastric tumors (8) . In breast cancers, targeted therapies such as trastuzumab and lapatinib are effective in clinic treatment (9) . However, HER2 aberrations in lung cancer showed resistance to these treatments likely through tissue-specific mechanisms (10) .
The current HER2 targeted therapies comprises of two groups, the TKIs and antibody based drugs. TKIs such as afatinib demonstrated efficacy from in vitro cell line assays (11, 12) and our previous preclinical study had indicated that the combination with afatinib and rapamycin showed efficacy against lung tumor driven by HER2 exon 20 insertions (13) . However, the clinical benefit of afatinib in HER2 positive lung cancer Author Manuscript Published OnlineFirst on January 3, 2018; DOI: 10.1158/1078-0432.CCR- patients remains unclear and more clinical trials are needed. Previous data indicated trastuzumab failed to demonstrate clinical benefit as a single therapy (14) . Recently, two trastuzumab-based trials showed some promise for either the ado-trastuzumabemtansine conjugate or trastuzumab/paclitaxel combination for HER2 positive lung cancers (15, 16) . Thus, new therapies need to be developed for lung cancer patients with HER2 aberrations.
HER2 aberrations found in NSCLC include both amplification and mutations and both lead to HER2 activation. While HER2 amplification and mutation (mainly in-frame exon 20 insertions) are found in 1-3% and 2-4%, respectively, of lung adenocarcinomas (1, 17, 18) , they are typically not associated with each other (17, 18) . Rather, they are proposed to be clinically distinct driver alterations that can be used to subdivide lung adenocarcinoma patients for targeted therapy (18, 19) .
Osimertinib (AZD9291) is a third-generation TKI which irreversibly and specifically targets both sensitizing and the resistant T790M-mutated EGFRs (20) . It has shown greater efficacy against EGFR T790M mutation than the standard platinum plus pemetrexed therapy and was thus recently fully approved by the FDA for metastatic EGFR T790M-positive NSCLC (21) . Osimertinib covalently binds the cysteine-797 residue of both sensitizing and T790M mutation of EGFR but spares the wildtype form (20) . This binding specificity leads to only mild side effects in a minority of patients as opposed to earlier generation TKIs that may cause severe toxicity due to their wildtype EGFR targeting (22) .
Research. When its targeting selectivity was explored, osimertinib was tested against a panel of 280 kinases and interestingly, this assay identified a limited number of kinases which could be inhibited by osimertinib, including HER2, HER4, ACK1, ALK, BLK et al (20) .
Considering the homology between HER2 and EGFR, we speculate that the covalent binding site for osimertinib may be C805 (analogous Cys797 to EGFR) of human HER2, which requires future investigation. Further cell line assays confirmed that HER2 could be targeted by osimertinib in vitro, implicating it as a potential HER2 targeting agent (20) .
However, it remains unknown whether osimertinib could demonstrate an in vivo antitumor efficacy against different HER2 aberrations in NSCLC.
Besides its role as an oncogenic driver, HER2 amplification is one of the major mechanisms of acquired resistance to first-generation TKIs in EGFR mutant lung cancers (12, 23) . Despite progress in EGFR-targeted therapy in lung cancers, intrinsic and acquired resistance remains a significant clinical challenge (12, 23) . EGFR T790M mutation is the most frequent event in acquired EGFR TKI resistance; HER2 amplification ranks second (12) . While osimertinib could efficiently overcome T790M mediated EGFR TKI resistance, its efficacy remains to be explored against other resistance mechanisms, such as HER2 amplification.
Additionally, epigenetic therapy has become increasingly promising as a new treatment strategy in NSCLC (24) . Recent studies have highlighted the abnormal epigenetic changes in many cancer types, and thus novel drugs targeting epigenetic modifiers have been developed (24, 25) . There are three subsets of epigenetic modifiers:
writers, readers and erasers (24) . Among the epigenetic readers, BET family members could recognize lysine acetylation of histones and are involved in chromatin remodeling (26) (27) (28) . Moreover, emerging evidence suggests that BET inhibitors could synergize with TKIs to boost anti-tumor responsiveness in a variety of cancer types (29) (30) (31) . In this study, we also aimed to explore whether BET inhibitors could overcome TKI resistance in HER2 aberrations.
Here, we designed a comprehensive preclinical study including individual HER2 alterations to test their responsiveness to osimertinib treatment, hoping to shed light on future HER2-targeted lung cancer therapeutics. Given that a prior study has shown that the BET inhibitor (BETi) JQ1 can boost lapatinib efficacy in HER2 positive breast cancer (30), we also explored the question of whether JQ1 combination treatment could enhance the anti-tumor response to osimertinib treatment in NSCLC.
Materials and Methods

GEMM generation
The procedure to generate the tet-op-hHER2 mouse cohort was described before (13, 32) . In short, a transgene DNA construct consisting of seven repeats of tetracycline operator, the wild-type human HER2 gene, and the SV40 poly (A) was injected into FVB/N blastocysts. PCR targeting the transgene was used to screen positive progeny.
Tet-op-hHER2 mice were crossed to Clara cell secretory protein (CCSP)-rtTA mice to obtain a tet-op-hHER2/CCSP-rtTA (HW) colony. The HW colony was fed with continuous doxycycline diet from at least 6 weeks of age. CCSP-rtTA/Tet-op-hEGFR Del-Luc and tet-op hER2 YVMA /CCSP-rtTA cohorts were generated as previously described (13, 33) . All mouse breeding and treatment experiments were performed with the approval of DFCI Animal Care and Use Committee.
Magnetic Resonance Imaging (MRI) and tumor volume quantification
Research. Lung tumors were monitored by MRI and 3D slicer was used to quantify the lung tumors as described before (34) (35) (36) .
Cell lines
NCI-H1781 cells were obtained from American Type Culture Collection (ATCC, Rockville, MD) and maintained in RPMI-1640 medium containing 10% FBS, 100 units/mL of penicillin and 100 ug/mL of streptomycin. Ba/F3-HER2 wt and Ba/F3-HER2 YVMA cells were generated and maintained as described (37) . (2947T) and β-actin (#4967) antibodies (all from Cell Signaling Technology). Then the blots were developed with ECL-Plus kits (GE healthcare) (38) (39) (40) .
CCK8 assay
IHC and H&E staining
Mice were euthanized and lung tissues were collected and fixed with 10% formalin.
Immunohistochemistry staining was performed as described (13, 35) 
Treatment study
HW, DH and SH26 mice were fed with doxycycline diets and lung tumors were monitored by MRI (34) . Tumor-bearing mice were treated with erlotinib (selleckchem, #S7786), osimertinib (AstraZeneca), afatinib (selleckchem, #S1011)or JQ1 and tracked by MRI every two weeks. Erlotinib (in 0.5% HPMC) was dosed at 50 mg/kg,afatinib (in 0.5% HPMC) was dosed at 20 mg/kg and osimertinib (in 0.5% HPMC) was dosed at 25 mg/kg daily all by oral gavage. JQ1, provided by Dr. Jun Qi and Dr. James Bradner (Dana Farber Cancer Institute, Boston, MA), was prepared in 10% DMSO (Thermo Fisher Scientific) and further diluted 1:10 with 10% 2-hydroxylpropyl β-cyclodextrin (Sigma). JQ1 was dosed to mice intraperitoneally (I.P.) at 50 mg/kg daily.
Fluorescent in situ hybridization (FISH)
The peripheral blood sample from the HW mouse was prepared for FISH by direct preparation (no culture or stimulation) with standard cytogenetic methods, and an airdried slide with nuclei was prepared and hybridized according to instructions provided with the commercial probes. A custom dual-color FISH probe was used to evaluate the presence and copy number of human HER2 in the blood sample using a commercial genomic probe for human HER2 (Abbott Molecular, labeled in orange/red, R) and as an internal control, a commercial mouse probe for D15Mit224, a single-copy region on chromosome 15 (ID Labs, labeled in green, G).
One hundred nuclei were scored, 50 cells each by two observers. All scorable nuclei had at least one orange and one green signal; the green (internal control) probe gave the expected 2 signal pattern in 92/100 cells, reflecting an excellent hybridization efficiency.
Copy number variation analysis using TaqMan assays
Genomic DNA was prepared from ear tissues from HW mice using Quick-DNA Miniprep Kit (Zymo Research) and used as templates in following real-time qPCR assays. Standard real-time qPCR was performed following the vendor's instruction for copy number assays. Taqman copy number assay targeting human HER2 (Thermo Fisher Scientific; assay ID Hs01074948_cn) was used together with TaqMan copy number reference assay (Thermo Fisher Scientific; mouse, Tert, #4458368).
Statistical analysis
Data were analyzed using mean ± standard error of the mean (SEM). Student's t-test was used for comparisons between two groups using GraphPad Prism software. P values < 0.05 were considered statistically significant (*); P values < 0.01 are marked **, and P values < 0.001 are marked ***.
Results
Generation and characterization of doxycycline induced lung-specific hHER2 wt
GEMM
Previous data has shown the in vitro efficacy of osimertinib against wildtype HER2 with cell line assays (20) . To confirm this in vitro efficacy and test whether osimertinib can target HER2 wt , we overexpressed wild-type human HER2 in Ba/F3 cells (37) . Treatment of Ba/F3-hHER2 wt cells with either osimertinib or first-generation TKI erlotinib for 6 hours showed that while erlotinib did not inhibit HER2 phosphorylation at up to 500 nM, osimertinib demonstrated potent activity in a dose-dependent manner from a concentration of 100 nM, confirming that osimertinib indeed targets human wildtype HER2 (Fig. 1A) .
Research. We further treated Ba/F3-hHER2 wt cells with either osimertinib or erlotinib for 72 hours to calculate growth inhibition (GI50) and found that osimertinib achieved a significantly lower GI50 (10.4 nM) compared to erlotinib (438 nM) (Fig. 1 B) . Taken together, these results confirmed the efficacy of osimertinib against human HER2 and efficiently inhibited HER2 phosphorylation at a low dose in vitro.
To study the in vivo role of osimertinib against hHER2, we first generated a tetOhHER2 transgenic mouse founder by injecting into FVB/N blastocysts a 4.75-kb DNA segment containing seven direct repeats of the tetracycline operator sequence followed by wild-type human HER2 ORF (open reading frame) and SV40 polyA(32) (Fig. 1 C; top).
The tetO-HER2 mouse founders were bred with CCSP-rtTA mice to generate the inducible lung-specific bitransgenic hHER2 wt /CCSP-rtTA (HW) cohorts, which harbor both activator and responder transgenes (Fig. 1 C; bottom) . To confirm that the hHER2 wt was integrated into mouse genome, we performed fluorescence in situ hybridization (FISH) using blood sample collected from HW mouse. FISH analysis showed that there were two copies of human HER2 in HW mouse genome (supplementary Fig. S1A and S1B). Real-time qPCR assays also confirmed two copies of hHER2, using mouse TERT gene as a control (supplementary Fig. S1B ). We further aimed to check hHER2 expression at protein level with doxy induction. Lungs of the doxycycline (doxy)-induced HW mice exhibited hHER2 expression after 5 weeks with doxy induction, and HER2 phosphorylation (pHER2) increased over time (Fig. 1 D) . To validate whether expression of HER2 was dependent on doxycycline, the doxy food was switched into normal diet for 3 days. After 3-day doxy removal, hHER2 expression was almost undetectable, confirming hHER2 expression was doxy-dependent ( Fig. 1 D) .
Research. To validate whether hHER2 expression can initiate lung cancer development, HW mice were fed with a continuous doxycycline diet and monitored by lung magnetic resonance imaging (MRI). Tumors began to form after 6 weeks and developed into high grade tumors after 16 weeks (Fig. 1E) . Immunohistochemistry (IHC) of HW tumors revealed high levels of HER2 and pHER2 (Fig. 1F, upper panel) . We also examined markers and found these HW tumors showed adenocarcinoma features with positive staining for TTF1 and low expression of SOX2 and p63 (13, 35, 41) (Fig. 1 F, lower panel) .
These histology features indicated the HW model mimicked the clinical setting as most lung cancers with HER2 aberrations are indeed adenocarcinomas. Having clarified that hHER2 could drive de novo tumorigenesis of lung adenocarcinomas, we further explored whether HER2 was also required for tumor maintenance. The doxycycline diet was replaced with normal food after tumor formation, and tumors disappeared two weeks after doxycycline diet removal (Fig. 1 G) . This confirmed HER2 was both an oncogenic driver in lung cancer and was required for tumor maintenance. Continuous MRI monitoring showed tumors developed faster 10 weeks after induction (supplementary Fig. S2 A) , and mice had a median survival of 19.4 weeks after doxycycline induction (supplementary Fig. S2 B) .
In vivo anti-tumor efficacy of osimertinib in HER2
wt GEMM.
The HW mice were fed with doxycycline food and lung tumors were monitored by MRI.
Osimertinib was then administered orally at 25 mg/kg daily, an equivalent dose to clinical 80mg QD in tumor-bearing HW mice (42) . Osimertinib treatment was efficacious after four weeks; in contrast, erlotinib and afatinib demonstrated limited anti-tumor response ( Fig. 2 A-B) . Both vehicle and erlotinib treated mice showed progressive
Research. 
disease by the 4-week time point (PD: more than 20% increase in tumor volume compared to baseline) and afatinib treated mice remained in stable disease (SD: between 30% decrease and 20% increase in tumor volume change). In contrast, all mice (n=7) treated with osimertinib showed significant tumor regression with mice achieving up to an 80% decrease in tumor volume compared to baseline (Fig. 2 B) .
To investigate whether osimertinib targeted HER2 signaling in vivo, we next performed a pharmacodynamic study. The tumor-bearing HW mice were dosed with HPMC, osimertinib or erlotinib for 3 days and then tumor nodules were collected. The tissue lysates were used for HER2 signaling analysis with western blot. Osimertinib effectively abolished HER2 phosphorylation and inhibited major downstream signaling targets such as pAKT and pERK (Fig. 2 C) . This pharmacodynamic data indicated the on-target efficacy of osimertinib against wildtype HER2 in vivo.
Long-term survival benefit with osimertinib treatment in HER2 wt mice
To further test whether osimertinib could maintain a durable anti-tumor response in HW mice, we performed long-term treatment with osimertinib or erlotinib in HW mice and monitored the tumor volume by lung MRI every two weeks. Osimertinib showed continuous anti-tumor efficacy for 16 weeks (Fig. 3 A) . The HW mice treated with osimertinib showed significantly longer progression-free survival (PFS) and overall survival (OS) compared to those treated with erlotinib ( Fig. 3 B-C) . This data demonstrated a long-term survival benefit for HW tumors with osimertinib treatment, which was consistent with the short-term efficacy and pharmacodynamic results. Taken
together, osimertinib treatment showed an on-target, efficacious and durable anti-tumor effect against HER2 in HW tumor model.
In vivo anti-tumor efficacy of osimertinib in EGFR del19
/HER2
wt GEMMs hHER2 wt overexpression was proven to be an oncogenic driver in lung cancer based on the HW mice model. Besides, it was also identified as an important mechanism underlying acquired resistance to TKIs such as erlotinib in EGFR mutant lung cancer patients (12) . Having clarified the anti-tumor efficacy of osimertinib against hHER2 as a driver oncogene in the HW model, we further tested osimertinib against co-expression of hHER2 in EGFR-mutant lung cancers.
There was no available GEMMs which could mimic the clinical setting of HER2 amplification-mediated acquired resistance in EGFR mutant lung cancers. We first treated CCSP-rtTA/Tet-op-hEGFR Del19-Luc (Del19) mice (33) with osimertinib or erlotinib. As expected, both drugs demonstrated robust anti-tumor efficacy after 4 weeks of treatment (supplementary Fig. S3 ). Next, we crossed Del19 mice with HW mice to produce tritransgenic tet-op EGFR-del19/hHER2 wt /CCSP-rtTA (Del19HW; DH) mice (Fig. 4 A) . In this model, lung tumors were co-driven by both EGFR del19 and HER2 wt .
Osimertinib efficiently inhibited DH tumors after two weeks (Fig. 4 B) . Erlotinib reduced tumors after two weeks as well, but tumors relapsed quickly after initial response (Fig. 4 B). To check the expression level of both oncogenes after treatment, pEGFR, HER2
and pHER2 were compared in the DH mice either before treatment or after relapse with erlotinib treatment with IHC. Two representative DH mouse lungs were examined: one mouse before erlotinib treatment and another treated with erlotinib for 12 weeks. While
on January 25, 2018. © 2018 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. the pEGFR level was high, HER2 expression remained low before treatment (Fig. 4 C; top panel). After relapse, pEGFR was nearly undetectable while HER2 and pHER2 levels increased significantly (Fig. 4 C; bottom panel) . Furthermore, we monitored the long-term efficacy for osimertinib treatment in DH mice and the PFS was significantly improved with osimertinib treatment (Fig. 4 D) . Taken together, these data indicated that osimertinib can also target HER2 together with an activating EGFR mutation.
Anti-tumor efficacy of combined osimertinib and JQ1 treatment against HER2 exon 20 insertions
Previous in vitro data showed modest efficacy of osimertinib against HER2 exon 20 insertion (20) . Having clarified the robust efficacy of osimertinib against HER2 amplification, we further tested its effect against HER2 exon 20 insertion mutations.
Ba/F3 cells stably expressing A775_G776insYVMA HER2 (Ba/F3-HER2 YVMA ), the most frequent exon 20 insertion, were treated with osimertinib or erlotinib for 6 hours.
Osimertinib inhibited pHER2 at 500 nM, while erlotinib did not (Fig. 5 A) . We also performed a 3-day proliferation assay and found osimertinib suppressed Ba/F3-HER2
YVMA at a much lower concentration (GI50=44 nM) compared to erlotinib (Fig. 5 B) .
However, HER2 YVMA (GI50=44 nM) was less sensitive than HER2 wt (GI50=10.4 nM).
Because Ba/F3 is a murine pro-B cell line, we next detected the inhibitory role of osimertinib in human lung cancer lines with HER2 mutations.
H1781 cells, a human lung cancer cell line harboring another exon 20 insertion (13),
HER2
G776insV_G/C , were treated with osimertinib for various times, from 6 hours to 5 days.
Osimertinib significantly inhibited pHER2 at 500 nM at all time points. Of note, total
Research. HER2 levels significantly increased with osimertinib treatment in a dose-dependent manner after one day (Fig. 5 C, lane 1-3) . Downstream phosphorylation of AKT and ERK was also suppressed by osimertinib treatment (Fig. 5 C, lane 1-3) . Interestingly, MYC was also inhibited by osimertinib at all time points, and p21 was reduced by osimertinib after 5 days (Fig. 5 C, lane 1-3 (Fig. 5 D) .
Osimertinib and JQ1 combination treatment against HER2
YVMA in vivo
Tet-op hER2 YVMA /CCSP-rtTA (SH26) mice were generated and used for preclinical study in our previous research as described (13) . To test osimertinib and JQ1
combination in vivo we treated tumor-bearing SH26 mice with either single agent or the two in combination. After two weeks, neither osimertinib nor JQ1 alone showed efficacy, but combination treatment led to significant tumor regression (Fig. 6 A) . After 4 weeks, only 3 out of 8 mice showed tumor regression with osimertinib treatment (Fig. 6 B) . In contrast, JQ1 and osimertinib combination showed a better anti-tumor benefit than single treatments (Fig. 6 B) . Moreover, the long-term treatment study indicated the PFS was greatly improved with JQ1 and osimertinib combination, compared with singleagent treatments in SH26 mice (Fig. 6 C) . These data provided the first in vivo evidence that although HER2 mutant tumors were resistant to osimertinib and JQ1 as single agents, they became vulnerable when treated with their combination.
Discussion
Both HER2 and EGFR (or HER1) belong to the ErbB / HER tyrosine kinase family which are activated by ligand binding and receptor dimerization (6) . Despite the rapid progress of EGFR targeted therapy (2, 25) , HER2 targeting remains an urgent clinical challenge in lung cancer. In this study, we clarified the unique response signature of lung cancer HER2 alterations to the FDA-approved third-generation TKI, osimertinib, using three (19, 43, 44) . But due to the limited patient number and low response rate within the small population, the overall response for each HER2 alteration subtype remains unclear.
Moreover, considering that HER2 amplification has only recently been considered as an The role of HER2 amplification as a lung cancer driver was identified from a recent cancer genomic study (17) . To our knowledge, we provided the first in vivo evidence that HER2 overexpression drives de novo tumorigenesis of lung adenocarcinomas.
Moreover, we also generated a unique DH model by crossing HW mice with EGFRdel19 mice and this DH strain closely mimicked HER2 overexpression in some EGFRmutant tumors with acquired resistance to first-generation TKIs. These two novel HER2 strains, provided the first available GEMM tools to test therapeutics against HER2 wt in
NSCLCs. HER2 was proposed as a potential resistance mechanism to osimertinib in EGFR T790M tumors (45) , but the potency of osimertinib against HW tumors demonstrated in our study may not support this hypothesis. It was also noteworthy that although osimertinib demonstrated a robust and durable anti-tumor response in HW mice model, acquired resistance to osimertinib developed after long-term treatment, which ultimately led to the death of HW mice. The mechanism underlying this resistance
needs further investigation, especially when osimertinib is used in clinic for patients with HER2 amplification. It would be interesting to address whether BRD4 inhibitors can overcome the resistance to osimertinib in HW mouse model.
The potent efficacy of osimertinib against HER2
wt also provides a rationale to test it in other cancers with HER2 amplification or overexpression, such as breast cancer.
HER2 positive breast cancer makes up about 20% of this cancer type and the HKI lapatinib is widely used in combination therapy for this subset of patients (9) . However, it may cause severe side effects such as diarrhea in a small proportion of patients (9) .
Considering the great efficacy of osimertinib as a single agent with minimum side effects, it may also benefit HER2 positive breast cancer treatment.
Compared with HER2 wt , osimertinib alone had limited efficacy against HER2 exon 20 insertions in vivo and we explored whether combination treatment may overcome this resistance to osimertinib. Previous studies have shown that BET inhibitor JQ1 could synergize with multiple TKIs in different cancer types (29) (30) (31) . In a subset of AML, JQ1
synergized with FLT3 TKI ponatinib to attenuate c-Myc, Bcl-2, CDK4/6 and increase p21, BIM and cPARP, thus inducing significant AML apoptosis (29) . In HER2-driven breast cancer, HKI lapatinib was found to induce expression of multiple kinases and reprogram the kinome, which could contribute to drug resistance (30) . However, JQ1
could suppress the kinase induction and kinome adaptation, thus making lapatinib response more durable (30) . Our previous studies showed JQ1 could both target Kras tumors and play an immunoregulatory role in NSCLC (46, 47) . Here we showed that JQ1
could also synergize with osimertinib against HER2 exon20 insertions by attenuating 
